For advanced HNSCC patients, novel immunotherapy agents—antibodies that target the programmed death-1 (PD-1)/programmed death-ligand 1 (PD-L1) system—offer improved effectiveness and relatively less toxicity as compared to standard therapies [11–13]. The gene discussed is CD274; the disease is head and neck squamous cell carcinoma.